In 599 men with metastatic androgen pathway modulation-sensitive prostate cancer with HRR gene alterations, talazoparib plus enzalutamide improved 3-year imaging-based PFS vs placebo plus enzalutamide (77% vs 56%; HR 0.48); serious adverse events 42% vs 32%.
RCTn = 599
Agarwal et al. PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer